Cure My Disease

Don't miss your cure!

 Log in / Sign up

Can a simple roadside test catch liver disease before it turns deadly?

NCT ID NCT06755632

Knowledge-focused Sponsor: Assistance Publique - Hôpitaux de Paris Source: ClinicalTrials.gov ↗

What the study statuses mean

This study's is highlighted.

Recruitment status, easiest to join first

Recruiting now This study
This trial is taking on new participants right now.
Not yet recruiting
Registered, but not yet taking participants.
By invitation only
Not open to general applications. Only people the study team invites can take part.
Paused
Paused for now. It may or may not start again.
Ongoing
Running, but no longer taking on new participants.
Completed
The trial has finished. Results may not be published yet.
Stopped early
Stopped early, before it reached the end. That can be for many reasons, including safety.
Cancelled
Cancelled before anyone took part.

Expanded access (not trials)

Expanded access
Not a trial. This treatment can be requested outside a study, case by case, for people who qualify.
Expanded access (paused)
Not a trial. The treatment can normally be requested outside a study, but is unavailable right now.
Expanded access (ended)
Not a trial. The treatment could once be requested outside a study, but no longer can.
Approved
The treatment has been approved, so it is available normally rather than through this programme.

When the status isn't known

Details not published
The full record has not been published yet, so there is little to show here.
Status unknown
This status has not been confirmed recently, so it may be out of date.

First seen Jul 23, 2026 · Last updated Jul 24, 2026 · Updated 1 time

Summary

This study aims to find undiagnosed cases of advanced liver fibrosis and viral hepatitis B and C in the general population of Seine Saint Denis, France. Using a combination of rapid diagnostic tests and a portable liver stiffness scanner (FibroScan), researchers will screen 600 adults in community settings. The goal is to measure how common these conditions are and to refer people who test positive to specialist care.

What this could mean

Our plain-language read of the trial. This is informational only, not medical advice or a prediction.

What this could lead to
If successful, this screening approach could identify many undiagnosed cases of liver disease and connect people to care earlier, potentially reducing complications and deaths.
What could go wrong
This is an observational screening study, not a treatment trial. It will measure how common liver fibrosis and hepatitis are, but it does not test any new therapy or intervention.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Study facts

What this study's own registry entry says, in plain language.

Phase

Not a phased trial

Phase numbers describe drug development. The registry uses this when they do not apply, as it does for trials of devices, procedures or behaviour changes, and for observational studies.

Participants

About 600 people

The number the study aims to enrol. It can still change while the study runs.

Started

Jun 2025

Expected to finish

Jun 2027

An estimate. End dates often move.

Lead sponsor

Other sponsor

The registry's catch-all category, for sponsors it does not file as a company, a government agency, or a research network.

Who can take part

This study's own entry requirements. Only the study team can say for certain whether you qualify.

Ages

18 years and older

Sex

Anyone

Healthy volunteers

Not accepted

This study is not open to healthy volunteers. The entry requirements below say who it is open to.

Show the full entry requirements

Copied word for word from the study's registry entry, so the wording is the study team's rather than ours.

Inclusion Criteria: * Age≥18 years * Collection of signed consent * Patients affiliated to a Social Security System Exclusion Criteria: * Pregnancy or breastfeeding * Subjects under AME * Persons under court protection * Guardianship or curatorship, * Safeguard of justice * Persons under psychiatric care without their consent * Persons admitted to a health or social institution for purposes other than research, * Patients of full age under legal protection (guardianship or curatorship) * Persons unable to express their consent.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for Advanced liver fibrosis are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Conditions

The condition(s) this trial relates to.

cirrhosis of liver Fibrosis fibrotic liver disease hepatitis B virus infection hepatitis C virus infection liver disorder

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

Liver pathology

How to take part

Only the study team decides who joins. These are the ways to reach them.

  1. The places running it

    1 site. The list below names each one and where it is.

  2. The official record

    ClinicalTrials.gov lists the study team's own contact details, including names and phone numbers. We don't republish those.

    Open the record ↗

  3. A doctor treating you

    A doctor who knows your case can contact a study site on your behalf, and can tell you whether this study is worth pursuing at all.

Contacts and locations

Locations

  • Avicenne Hospital

    RECRUITING

    Bobigny, 93000, France

  • Hepatology department -Hospital Avicenne

    WITHDRAWN

    Bobigny, 93100, France

More trials for these conditions

Other studies related to the condition(s) this trial covers.